Steven Cohen Stoke Therapeutics, Inc. Transaction History

Point72 Asset Management, L.P.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$4.12 - $14.17 $586,926 - $2.02 Million	142,458 New	142,458 $1.92 Million
Q1 2023 May 15, 2023	SELL	$7.65 - $10.38 $147,576 - $200,240	-19,291 Reduced 67.22%	9,409 $78,000
Q4 2022 Feb 14, 2023	BUY	$7.07 - $15.69 $202,909 - $450,303	28,700 New	28,700 $264,000
Q1 2022 May 16, 2022	SELL	$17.19 - $26.1 $4.02 Million - $6.11 Million	-233,997 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$18.11 - $30.72 $4.24 Million - $7.19 Million	233,997 New	233,997 $5.61 Million
Q4 2020 Feb 16, 2021	SELL	$33.62 - $61.93 $1.32 Million - $2.43 Million	-39,244 Closed	0 $0
Q3 2020 Nov 16, 2020	BUY	$22.23 - $37.48 $872,394 - $1.47 Million	39,244 New	39,244 $1.31 Million

125

57.6M

9.3K

35.2K

Ticker STOK
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,419,300
Market Cap $386M
Description
Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops novel antisense oligonucleotide (ASO) medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output to design ASOs to precisely upregulate protein expression. I...

Get notified when there are updates to the investment portfolio of Point72 Asset Management, L.P., based on Form 13F filings with the SEC.

Stay updated on Point72 Asset Management, L.P. and Steven Cohen with notifications on news.